According to data published yesterday in the Journal of the National Cancer Institute, after adjustment for inflation, the average cost for treatment of a newly-diagnosed patient with prostate cancer actually fell by $196 (1.0 percent) between 1991 and 2002, to an average of $18,261 (because fewer men got surgery). By comparison the costs of treating newly diagnosed [...]
Filed under: Uncategorized | 2 Comments »
According to a report in the June 1 issue of Cancer, researchers have uncovered new information about why metastatic prostate cancer may progress following failure of androgen-deprivation therapy (ADT). … MORE …
Filed under: Uncategorized | No Comments »
In reviewing the many prostate cancer presentations given at the AUA during last week, we have noted several that are certainly worth bringing to the attention of our readers and that have not previously been reported. … MORE …
Filed under: Uncategorized | 7 Comments »
The following major new content pages have been added to the main web site over the past week:
High intensity focused ultrasound in treatment of early stage (localized) prostate cancer
Orchiectomy in treatment of metastatic prostate cancer
Luteinizing hormone releasing hormone (LHRH) agonists in treatment of metastatic prostate cancer
Luteinizing hormone releasing hormone (LHRH) antagonists in treatment of metastatic prostate cancer
Nonsteroidal [...]
Filed under: Uncategorized | No Comments »
The “New” Prostate Cancer InfoLink is pleased to announce that Judd W. Moul, MD, FACS, professor and chief, Division of Urologic Surgery, and director of the Duke Prostate Center, Duke University Health System, Durham, NC, has agreed to become the chairman of a scientific advisory board to our web services. In forthcoming weeks we [...]
Filed under: Uncategorized | No Comments »
Between the general exhaustion of the urology community after the AUA and the Memorial Day “long weekend” here in the USA, it’s likely to be pretty quiet on the prostate cancer front for at least a couple of days. Don’t be surprised if there’s little to report before Tuesday, May 27. … And don’t worry, [...]
Filed under: Uncategorized | No Comments »
The “New” Prostate Can InfoLink does not believe that recently published data necessarily implies that prostate biopsy is associated with increased risk of death at 120 days. However, the data presented in a paper just published does suggest that a careful analysis of this risk may be important. … MORE
Filed under: Uncategorized | No Comments »
It appears that extending the amount of time over which radiotherapy (RT) is given to patients in treatment of localized prostate cancer may increase the risk for biochemical failure in a subset of those patients — the ones already at low risk for rapidly progressive disease. Patients at low risk for progressive prostate cancer who [...]
Filed under: Uncategorized | No Comments »
According to an abstract of a presentation to be given at the American Society of Clincial Oncology (ASCO) annual meeting in a couple of weeks, Amgen Inc.’s experimental drug denosumab was more effective than zoledronate (Zometa) in preventing fractures in cancer patients — at least in early test results. … MORE
Filed under: Uncategorized | No Comments »
Macdonald et al. have reported that, based on an analysis of data from the CaPSURE™ database, salvage radiotherapy (SRT) is optimal for patients with low pre-SRT PSA levels, long PSA doubling times, and favorable pathologic features. Patients who do not meet these criteria may benefit significantly less from SRT, particularly if the potential for complications [...]
Filed under: Uncategorized | No Comments »
